SWHR Provides Comments to CMS on Medicare Coverage Policy for Monoclonal Antibodies Directed Against Amyloid for the Treatment of AD


Published 2/9/22

The Society for Women’s Health Research provided comments to the Centers for Medicare & Medicaid Services (CMS) in response to its proposed National Coverage Determination decision memorandum on Medicare coverage for monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease. SWHR’s comments were aimed at ensuring that CMS’ final policy enables, and does not unnecessarily restrict, patients’ access to safe, effective, and potential quality-of-life improving treatments for AD.

Read The Comments